

ESTRO

29
ESTRO

WWW.ESTRO.ORG

EL 12 DE SEPTIEMBRE < 2010

12 DE SETEMBRO < 2010

BARCELONA < ESPAÑA

/// JORNADA PARA LAS ASOCIACIONES NACIONALES ///

/// DIA PARA AS SOCIEDADES NACIONAIS ///

12 DE SETEMBRO DE 2010 • BARCELONA, ESPANHA JORNADA PARA AS SOCIEDADES NACIONAIS

Pela terceira vez, depois de Liepzig (2006) e Göteborg (2008), a ESTRO organizou uma Jornada para as Sociedades Nacionais de Radioterapia Oncologia no contexto do seu 29 Congresso bianual de Barcelona (Espanha), de 12 a 16 de Setembro. A primeira Sessão intitulada National Day é patrocinado pela SEOR (Espanha), ALATRO (América Latina) e SPRO (Portugal). A segunda Sessão intitulada *Young Scientists Meeting* é patrocinada pela SEOR (Espanha), ALATRO (América Latina), SPRO (Portugal) e SFRO (França).

O *National Day* está dedicado à discussão de diferentes aspectos do tratamento do cancro de cabeça e pescoço mediante conferências por especialistas reconhecidos e apresentação de trabalhos orais por parte das diferentes Sociedades. Os idiomas aceites para esta reunião tendo em conta as línguas dos diferentes países são o espanhol e o português.

O *Young Scientist* estará dedicado aos jovens investigadores de Espanha, França, Portugal e América Latina (Menos de 40 anos). Esta segunda reunião tem como objectivo dar aos jovens uma visão do caminho para que se dirige a ESTRO no que diz respeito à formação e linhas de investigação clínica e básica.

Esperando poder contar com o maior número de sócios no *National Day* e no *Young Scientist Meeting*, recebam os nossos mais afectuosos cumprimentos.

Presidentes SEOR, Ferran Guedea
Presidente SPRO, Lourdes Trigo
Presidente ALATRO, Cuathemoc de la Peña
Presidente SFRO, Eric Lartigau
Organizador National Day, Angeles Rovirosa (roviroso@clinic.ub.es)
Organizador Young Scientist Meeting, Luis Perez Romasanta (lapr06@gmail.com)
Responsable en ESTRO: Eralda Azizaj (eazizaj@estro.org)

12 SEPTEMBRE 2010 • BARCELONE, ESPAGNE JOURNÉE DES SOCIÉTÉS NATIONALES

Pour la troisième fois, après (2006) et Göteborg (2008), l'ESTRO va organiser une journée des sociétés nationales de radiothérapie dans le cadre de son 29^{ème} Congrès à Barcelone, du 12 au 16 septembre 2010. La Journée *National Day* est placée en première partie sous les auspices des Sociétés SEOR (Espagne), ALATRO (Amérique latine) et SPRO (Portugal) et en seconde partie la session *Young Scientists Meeting* sous les auspices de SEOR, ALATRO, SPOR et SFRO (France).

La *Young Scientist Meeting* est dédiée aux jeunes chercheurs et cliniciens d'Espagne, France, Portugal et Amérique Latine de moins de 40 ans. Cette réunion a pour vocation de montrer aux jeunes la politique de formation de l'ESTRO et de faire présenter par les jeunes orateurs sélectionnés des travaux de recherche clinique et biologique.

Nous espérons que vous serez nombreux au National Day et au Young Scientist Meeting, très cordialement,

Président SEOR, Ferran Guedea
Président SPOR, Lourdes Trigo
Président ALATRO, Cuathemoc de la Peña
Président SFRO, Eric Lartigau
Organisateur National Day, Angeles Rovirosa (roviroso@clinic.ub.es)
Organisateur Young Scientist Meeting, Luis Perez Romasanta (lapr06@gmail.com)
Responsable à l'ESTRO: Eralda Azizaj (eazizaj@estro.org)

12 DE SEPTIEMBRE DEL 2010 • BARCELONA, ESPAÑA JORNADA PARA LAS SOCIEDADES NACIONALES

Por tercera vez, después de Liepzig (2006) y Göteborg (2008), ESTRO ha organizado una Jornada para las Sociedades Nacionales de Oncología Radioterápica en el contexto de su 29 Congreso bianual de Barcelona (España), del 12 al 16 de septiembre. La Jornada está auspiciada por SEOR (España), ALATRO (Latinoamérica) y SPRO (Portugal) en su primera parte que se titula *National Day* y esta auspiciada por SEOR (España), ALATRO (Latinoamérica), SPOR (Portugal) y SFRO (Francia) en su segunda parte que se llama *Young Scientists Meeting*.

El *National Day* está dedicado a la discusión de diferentes aspectos del tratamiento del cáncer de cabeza y cuello mediante conferencias por especialistas reconocidos y presentación de trabajos orales por parte de las diferentes sociedades. Los idiomas aceptados para esta reunión teniendo en cuenta las lenguas de los diferentes países son el español y el portugués.

El *Young Scientist* estará dedicado a los jóvenes investigadores de España, Francia, Portugal y Latinoamérica (Menos de 40 años). Esta segunda reunión intentará dar a los jóvenes una visión del camino que está siguiendo la ESTRO en cuanto a formación y líneas de investigación clínicas y básicas.

Esperando poder contar con el mayor número de ustedes en el *National Day* y el *Young Scientist Meeting*, reciban nuestros más afectuosos saludos,

Presidentes SEOR, Ferran Guedea
Presidente SPOR, Lourdes Trigo
Presidente ALATRO, Cuathemoc de la Peña
Presidente SFRO, Eric Lartigau
Organizador National Day, Angeles Rovirosa (roviroso@clinic.ub.es)
Organizador Young Scientist Meeting, Luis Perez Romasanta (lapr06@gmail.com)
Responsable en ESTRO: Eralda Azizaj (eazizaj@estro.org)

NATIONAL DAY - REUNIÓN CONJUNTA ALATRO, SEOR, SPRO ESTRO 29TH, 12 DE SEPTIEMBRE DE 2010 • BARCELONA, ESPAÑA

- 09.30 - 09.35 > Bienvenida: Presidente de ESTRO
- 09.35 - 11.05 > **SYMPOSIUM: "CÁNCER DE CABEZA Y CUELLO: ESTADO DEL ARTE"**
MODERADOR: Dra. Angeles Rovirosa. España
- 09.35 - 10.05 > Tratamiento del cáncer de laringe: Estado del arte
CONFERENCIANTE: Dr. Jordi Giralt (SEOR)
- 10.05 - 10.35 > Tratamiento del cáncer de cavidad oral y and orofaringe: Estado del arte
CONFERENCISTA: Dr. Gustavo Sarrias (ALATRO)
- 10.35 - 11.05 > Tratamiento del cáncer de nasofaringe: Estado del arte
CONFERENCIANTE: Dra. Ana Cleto (SPRO)
- 11.05 - 13.05 > **COMUNICACIONES ORALES EN CÁNCER DE CABEZA Y CUELLO**
MODERADORES: Dra. Adela Poitevin (ALATRO), Dra. Judit Ramos (SPRO), Dr. José Medina (SEOR)
- Primera comunicación / Segunda comunicación / Tercera comunicación / Cuarta comunicación / Quinta comunicación / Sexta comunicación / Séptima comunicación / Octava comunicación
- 13:05 - 13:15 > **CONCLUSIONES Y CLAUSURA DE LA SESIÓN:**
Organizadores del National day, Presidentes de SEOR, ALATRO y SPRO
- 13.15 - 14.00 > Comida

NATIONAL DAY YOUNG SCIENTISTS SESSION (ALATRO, SEOR, SFRO, SPRO) ESTRO 29TH, SEPTEMBER 12TH • BARCELONA, SPAIN

- 14.00 - 14.10 > Introduction and presentation of the Jury
President of SEOR, President of SPRO, President of ALATRO, Local organizer and the young scientists coordinating the session: A. Navarro (Spain), S. Rivera (France) and L. Perez Romasanta (Spain)
- 14.10 - 14.30 > **THE EXPERIENCE OF YOUNG SCIENTISTS MEETINGS IN POLAND**
J. Malicki (Poland)
- 14.35 - 14.55 > **RESEARCH, FROM THE LAB TO THE CLINIC**
A. Begg (NL)
- 15.00 - 15.15 > First communication
- 15.15 - 15.30 > Second communication
- 15.30 - 15.45 > Third communication
- 15.45 - 16.00 > Fourth communication
- 16.00 - 16.15 > Fifth communication
- 16.15 - 16.30 > Sixth communication
- 16.30-16.45 > Conclusions

DIA NACIONAL - REUNIÃO DA ALATRO, AERO E SPRO ESTRO 29TH, 12 DE SETEMBRO • BARCELONA, ESPANHA

- 09.30 - 09.35 > Boas-vindas pelo Presidente da ESTRO
- 09.35 - 11.05 > **SIMPÓSIO: CABEÇA E PESCOÇO: ESTADO DA ARTE**
CONFERÊNCIAS: Presidente: Dra. Angeles Rovirosa
- 09.35 - 10.05 > Tratamento do cancro da Laringe: Estado da arte
PALESTRANTE: Dr. Jordi Giralt (SEOR)
- 10.05 - 10.35 > Tratamento do Cancro da cavidade oral e orofaringe: Estado da arte
PALESTRANTE: Dr. Gustavo Sarrias (ALATRO)
- 10.35 - 11.05 > Tratamento do Cancro da nasofaringe: Estado da arte
PALESTRANTE: Dra. Ana Cleto (SPRO)
- 11.05 - 13.05 > **COMUNICAÇÕES LIVRES: CANCRO CABEÇA E PESCOÇO**
PRESIDENTES: Dra. Adela Poitevin, Dra. Judite Ramos, Dr. José Medina
- Primeira Comunicação (10' apresentação) / Segunda Comunicação (10' apresentação) / Terceira Comunicação (10' apresentação) / Quarta Comunicação (10' apresentação) / Quinta Comunicação (10' apresentação) / Sexta Comunicação (10' apresentação) / Sétima Comunicação (10' apresentação) / Oitava Comunicação (10' apresentação)
- 13:05 - 13:15 > **CONCLUSÕES E ENCERRAMENTO:**
Organizadores do Dia Nacional, Presidentes da SEOR, ALATRO e SPRO
- 13.15 - 14.00 > Almoço

NATIONAL DAY YOUNG SCIENTISTS SESSION (ALATRO, SEOR, SFRO, SPRO) ESTRO 29TH, SEPTEMBER 12TH • BARCELONA, SPAIN

- 14.00 - 14.10 > Introduction and presentation of the Jury
President of SEOR, President of SPRO, President of ALATRO, Local organizer and the young scientists coordinating the session: A. Navarro (Spain), S. Rivera (France) and L. Perez Romasanta (Spain)
- 14.10 - 14.30 > **THE EXPERIENCE OF YOUNG SCIENTISTS MEETINGS IN POLAND**
J. Malicki (Poland)
- 14.35 - 14.55 > **RESEARCH, FROM THE LAB TO THE CLINIC**
A. Begg (NL)
- 15.00 - 15.15 > First communication
- 15.15 - 15.30 > Second communication
- 15.30 - 15.45 > Third communication
- 15.45 - 16.00 > Fourth communication
- 16.00 - 16.15 > Fifth communication
- 16.15 - 16.30 > Sixth communication
- 16.30 - 16.45 > Conclusions

BARCELONA • SUNDAY SEPTEMBER 12, 2010
OPENING CEREMONY

18.00-19.15 > OPENING REMARKS
J. Bourhis (FR) - Chair of Scientific Programme Committee
D. Georg (AT) - Chair of Scientific Programme Committee
F. Guedea (ES) - Chair of National Organizing Committee
N. Jornet (ES) - Chair of National Organizing Committee

HPV AND HUMAN CANCER:
 A 30-YEAR RESEARCH STORY
 AND AN AVENUE FOR PREVENTION
X. Bosch (ES)

BARCELONA • MONDAY SEPTEMBER 13, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (BT)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)	Room 8
TEACHING LECTURE 08:00 - 08:40	Clinical relevance of molecular signaling in radiotherapy <i>C. Belka</i> (DE)	Hypofractionated breast cancer protocols & partial breast irradiation techniques <i>J. Jassem</i> (PO)	Imaging for brachytherapy <i>R. Pötter</i> (AT)	New ICRU recommendations for IMRT <i>V. Grégoire</i> (BE)	New Core Curriculum for Medical Physicists in the field of Radiotherapy <i>T. Eudaldo</i> (ES) Revised Core Curriculum for RTTs <i>M. Coffey</i> (IE)	Exploiting DNA repair <i>C. Venis</i> (NL)	Overview of rectal cancer <i>C. Marijnen</i> (NL)	07:30 - 10:00 Lung Contouring <i>X. Geets</i> (BE) <i>U. Nestle</i> (DE)
SYMPOSIUM 08:45 - 10:00	Novel molecular targeting and radiation clinical update JOINT SESSION WITH BIOLOGY • PARP inhibitors <i>A. Chalmers</i> (UK) • Histone Deacetylase inhibitors in radiotherapy - from preclinical concept to clinical therapy <i>A. Ree</i> (NO) • mTOR inhibition <i>B. Wouters</i> (CA)	New approach in radiotherapy of breast cancer • Genotyping: prediction of local failure and toxicity <i>J. Alsner</i> (DK) • Technical challenges in locally advanced breast cancer <i>S. Bodis</i> (CH) • Role of radiotherapy in DCIS <i>Ph. Poortmans</i> (NL)	Image-fusion techniques in brachytherapy BRACHYPHYSICS SESSION • Implementation in gynaecological IGBT <i>C. Kirisits</i> (AT) • Implementation in prostate brachytherapy <i>A. Polo</i> (UK) • Can image fusion prove brachytherapy in the head and neck region? <i>IK. Kalkman-Deurloo</i> (NL)	Can Quality Control be reduced without compromising quality? • Introduction: Are we doing too much QA? <i>N. Jornet</i> (ES) • QA management in RT: How to optimize the efficiency with QA management tools? <i>T. Knöös</i> (SE) • Failure mode and effect analysis (FMEA) Practical example in IMRT <i>S. Huq</i> (USA) • The role of process control in quality improvement <i>T. Pawlicki</i> (USA)	What can functional imaging add in treatment planning? JOINT SESSION PHYSICS, BIOLOGY, CLINICAL • Functional imaging of liver in stereotactic radiotherapy for liver tumours <i>M. Hoyer</i> (DK) • Functional imaging for delineation and characterization of prostate tumours <i>U. van der Heide</i> (NL) • The biologically effective dose at the voxel level <i>M. Joiner</i> (USA)	New Predictive tools in radiotherapy • Prognostic significance of tumor hypoxia inducible factor-1alpha expression <i>C. West</i> (UK) • Biomarkers of clinical responsiveness in brain tumor patients: progress and potential <i>A. Chakravarti</i> (USA) • Prognostic gene expression signatures for radiotherapy <i>L. van't Veer</i> (NL)	Management of rectal cancer (part I) JOINT SESSION WITH CLINICAL • Optimal Results with a Multidisciplinary Team Approach <i>M.A. Gambacorta</i> (IT) • Image-guided radiotherapy in rectal cancer: challenges and pitfalls <i>K. Haustermans</i> (BE) • Managing the consistency of the rectal volume. How to know where the rectum and the tumor is <i>R. De Jong</i> (NL)	
10:00 - 10:30	Coffee							
PROFFERED PAPERS 10:30 - 11:30	Proffered Papers	Debate: Partial breast irradiation should be considered a standard of care in 2010... • In favour of the motion <i>R. Orecchia</i> (IT) • Against the motion <i>J. Yarnold</i> (UK)	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers

	Room 1 (CL)	Room 2 (CL)	Room 3 (BT)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)
<p>PRESIDENTIAL SYMPOSIUM 11:30 - 12:15</p> <ul style="list-style-type: none"> • The future of radiation oncology: The vision of ESTRO <i>J. Bourhis (FR)</i> • Integration in the European Multidisciplinary scene: The vision of ECCO <i>M. Baumann (DE)</i> 							
<p>AWARD LECTURE 12:15 - 12:45</p> <p>Van der Schueren Award Linking research and education: gynaecologic brachytherapy as template for future ESTRO activities? <i>R. Pötter (AT)</i></p>							
<p>12:45 - 14:30</p> <p>Lunch - Poster viewing - Satellite Symposia</p>							
<p>SYMPOSIUM 14:30 - 15:45</p> <p>Normal Tissue effects (recognition / prevention / intervention)</p> <ul style="list-style-type: none"> • Multifactorial prediction of radiation-induced lung-toxicity: Beyond V20 and mean lung dose <i>Ph. Lambin (NL)</i> • Rectum <i>D. Dearnaley (UK)</i> • Salivary glands damage vs xerostomia: are they synonymous? <i>A. Eisbruch (USA)</i> 	<p>Management of early NSCLC</p> <ul style="list-style-type: none"> • Stereotactic radiotherapy <i>E. Lartigau (FR)</i> • Surgical approach <i>M. Weder (CH)</i> • Intervential radiology <i>J. Palussière (FR)</i> 	<p>Role of breast therapy outside of partial breast irradiation</p> <ul style="list-style-type: none"> • How to boost in breast conservation radiotherapy? <i>E. Van Limbergen (BE)</i> • Re-irradiation by brachytherapy in second breast conserving treatments. An alternative to salvage mastectomy? <i>C. Polgar (HU)</i> • Brachytherapy in recurrences of the previously irradiated chest wall <i>P. Niehoff (DE)</i> 	<p>Optimization strategies and advanced planning</p> <ul style="list-style-type: none"> • Robustness of a treatment plan <i>J. Unkelbach (USA)</i> • Beam angle optimisation <i>B. Heijmen (NL)</i> • Comparing IMRT treatment planning systems <i>C. Ceberg (SE)</i> 	<p>Dose painting: the experts point of view</p> <p>JOINT SESSION</p> <ul style="list-style-type: none"> • Physicist aspects <i>W. Tome (USA)</i> • Biological aspects <i>D. Zips (DE)</i> • Clinician perspective <i>W. De Neve (BE)</i> 	<p>Promises and pitfalls of PARP inhibitors</p> <ul style="list-style-type: none"> • The increasing complexity of PARP family proteins - implications for cancer therapy <i>T. Helleday (UK)</i> • The potential role of PARP inhibitors in radiation oncology <i>A. Chalmers (UK)</i> • Hypoxia and PARP inhibitors: Taking advantage of contextual synthetic lethality <i>R. Bristow (CA)</i> 	<p>Management of Rectal cancer (part II)</p> <ul style="list-style-type: none"> • What is the most appropriate CT planning procedure for Pre-operative Irradiation <i>D. de Haas (NL)</i> • Managing and preventing side effects <i>P. Maingon (FR)</i> • Nutrition, quality of life and clinical outcomes after RT: Long term FU of a prospective randomised controlled trial in colorectal cancer <i>P. Ravasco (PT)</i> 	
<p>15:45 - 16:15</p> <p>Coffee</p>							

	Room 1 (CL)	Room 2 (CL)	Room 3 (BT)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)
<p>PROFFERED PAPERS 16:15 - 17:30</p> <p>Up-date of phase III randomized trials</p> <ul style="list-style-type: none"> • Update of RTOG accelerated versus convention RT-CT in HNC <i>K. Ang (USA)</i> Discussant: <i>W. Budach (DE)</i> • Breast cancer: Up-date of the FAST and START trials <i>J. Yarnold (UK)</i> Discussant: <i>A. Fourquet (FR)</i> • Update on RTOG 94-08: Phase III results of Short course Androgen deprivation with RT in low- and intermediate-risk prostate cancer <i>W. Shipley (USA)</i> Discussant: <i>M. Bolla (FR)</i> • Update on PROG 95-09: 10 year outcomes of 79 Gy versus 70 Gy conformal RT in low- and intermediate-risk Prostate cancer <i>W. Shipley (USA)</i> Discussant: <i>D. Dearnaley (UK)</i> • Update of the EORTC Boost trial <i>H. Bartelink (NL)</i> Discussant: <i>tbc</i> 	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>
<p>HONORARY MEMBERS 17:30 - 16:45</p> <p>Can closing the visualization gap make cancer a chronic disease? <i>TR. Mackie (USA)</i></p> <p>Individual patient data meta-analysis and radiotherapy in head and neck and lung cancer <i>JP. Pignon (FR)</i></p> <p>Managing a randomized clinical trial in a developing country--Pakistan: problems and experiences <i>N. Bagum (Pakistan)</i></p>							
<p>POSTER RECEPTION 18:45 - 20:00</p>							

BARCELONA • TUESDAY SEPTEMBER 14, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (BT)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)	Room 8 (YOUNG)	Room 9
TEACHING LECTURE 08:00 - 08:40	The ECCO-AA-CR-ASCO FLIMS course for young investigators: A first step toward successful clinical trials <i>Ph. Lambin (NL)</i>	Rectum: agreement and disagreement within the EURECA consensus conference <i>D. Sebag-Montefiore (UK)</i>	Quality assurance of real-time brachytherapy planning and delivery <i>B. Al Qaisieh (UK)</i>	Interaction of protons and light ions with matter <i>H. Palmans (UK)</i>	Information sharing, workflow, and patient care in radiation oncology <i>J. Palta (USA)</i>	Targeting lactate exchanges in tumours: from basic characterization to new therapeutic applications <i>P. Sonveaux (BE)</i>	Radiotherapy practice for NSCLC <i>C. Le Pechoux (FR)</i>	How to get your scientific message across: from abstract to poster/oral presentation/plenary session <i>M. Brada (UK)</i>	07:30 - 10:00 Rectal Contouring <i>C. Marijnen (NL)</i> <i>M. Gambacorta (IT)</i>
SYMPOSIUM 08:45 - 10:00	Non Prostate GU malignancies • Organ preservation in bladder carcinoma, including up-date of randomized trials <i>J. Dunst (DE)</i> • An update on the management of penil carcinoma, including brachytherapy <i>A. Kiltie (UK)</i> • Can we skip radiotherapy in testis carcinoma? <i>A. Horwich (UK)</i>	New strategies in the management of upper GI malignancies • Pancreatic adenocarcinoma: Light at the end of the tunnel? <i>T. Brunner (UK)</i> • Oesophageal cancers: new strategies <i>J.F. Bosset (FR)</i> • Optimal treatment of gastric cancer, past present and future directions <i>M. Verheij (NL)</i>	Vaginal cuff irradiation by brachytherapy: why, where and how much? • Patient selection for vaginal cuff brachytherapy in endometrial cancer <i>C. Hale-Meder (FR)</i> • What is the appropriate dose and schedule for vaginal cuff irradiation? <i>T. Hellebust-Paulsen (NO)</i> • Are optimized techniques necessary in prophylactic vaginal cuff brachytherapy (with special focus on complications) <i>N. Tuncel (TR)</i>	ESTRO / PTCOG JOINT SYMPOSIUM Current challenges in proton and ion beam therapy • Improving gantry-based proton scanning beyond current state of the art <i>E. Pedroni (CH)</i> • Positioning and motion with or without scanned particle beams? <i>A. Mazal (FR)</i> • Enlarging the clinical use of protons <i>T. Delaney (USA)</i>	New insights in PET imaging JOINT SESSION BIOLOGY, CLINICAL • Novel PET-tracers for potential future application in radiation oncology <i>W. Oyen (NL)</i> • Kinetic models -review <i>D. Thorwarth (DE)</i> • The SUV and its dependencies -silly useless value? <i>R. Boellaard (NL)</i>	Tumour metabolism as a new target • Dialogue between glycolytic and oxidative tumour cells <i>O. Feron (BE)</i> • H2AX in hypoxia and neovascularization <i>E. Hammond (USA)</i> • Autophagy and metabolism <i>B. Wouters (CA)</i>	The use of PET-CT for lung cancer • Overview of PET imaging for Lung cancer <i>U. Nestle (DE)</i> • How to perform a PET/CT scan of lung cancer patients <i>M. Federspiel (DK)</i> • Lung tumor motion during treatment: should we match on bone or on tumour? <i>C. Hoinkis (DE)</i>	Hot developments in radiation oncology • Biology <i>M.C. Vozenin-Brotans (FR)</i> • Physics <i>R. Moeckli (CH)</i> • RTT <i>M. Mast (NL)</i> • Clinical radiotherapy <i>G. Lammering (NL)</i>	
10:00 - 10:30	Coffee								

BARCELONA • TUESDAY SEPTEMBER 14, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (BT)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)	Room 8 (YOUNG)
PROFFERED PAPERS 10:30 - 11:30	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Moving Poster Session
AWARD LECTURE 11:30 - 12:00	Regaud Award Translational Research in Radiation Oncology: Opening New Windows of Opportunity <i>J. Bernier (CH)</i>							
12:00 - 12:45	Highlights of proffered papers							
12:45 - 14:30	Lunch - Poster viewing - Satellite Symposia							
SYMPOSIUM 14:30 - 15:45	ESTRO / EAU JOINT SYMPOSIUM Multidisciplinary treatment of prostate carcinoma • Post-op - immediate vs salvage treatment - a radiation oncology view <i>T. Wiegel (DE)</i> • Post-op - immediate vs salvage treatment - a surgical view <i>B. Tombal (BE)</i> • Value of hypofractionation and brachytherapy <i>P. Hoskin (UK)</i>	Updates and new strategies in the management of rectal cancer • Up-date of randomized trials including STAR trial on oxaliplatin and ACCOR 3 <i>J.P. Gerard (FR)</i> • Organ preservation in rectal cancer <i>C.S. Rodel (DE)</i> • Tailored rectal cancer treatment by nomograms <i>V. Valentini (IT)</i>	Timing of brachytherapy boost treatments • Introduction <i>J. Lindegaard (DK)</i> • Does radiobiology help in timing of a brachytherapy boost? <i>B. Jones (UK)</i> • Does imaging help in timing of a brachytherapy boost? <i>A. Grosu (DE)</i>	New biological principles for describing volume effects JOINT SESSION WITH BIOLOGY • Tissue and organ interactions in the development of normal tissue damage: implications for NTCP modelling <i>P. van Luijk (NL)</i> • Spatial dose statistics <i>C.M. Andreassen (DK)</i> • Neural networks for toxicity prediction <i>M. Partridge (UK)</i>	Rotational IMRT JOINT SESSION WITH CLINICAL • Limits in optimization of Arc IMRT <i>M. Alber (DE)</i> • Clinical experience with VMAT <i>F. Lohr (DE)</i> • Clinical experience with RapidArc <i>W. Verbakel (BE)</i> • Critical comparison of single / few Arcs and standard IMRT <i>D. Verellen (BE)</i>	ESTRO / RRS JOINT SYMPOSIUM Molecular targeting to modify normal tissue toxicity • Mitigation of radiation nephropathy <i>E. Cohen (USA)</i> • Heart toxicity <i>F. Stewart (NL)</i> • Oxidative stress and inflammation of late lung effects <i>J. Williams (USA)</i>	Position verification JOINT SESSION WITH PHYSICS • Overview of systematic and random errors <i>H. de Boer (NL)</i> • Verification images: How often and who should read them and utilise information? <i>KFJ Nikolaus Metz III (AT)</i> • Cone beam CT: clinical implementation <i>H. McNair (UK)</i>	ESTRO / CARO JOINT SYMPOSIUM The rapid implementation of new technology in the field of Radiation Oncology • Targeted nanoparticles radiosenstization - How can we make it work? <i>J.P. Pignol (CA)</i> • Technological implementation based on tomotherapy experience: Using tomotherapy as a "gold-standard" in pareto-like planning comparisons with other advanced photon delivery techniques <i>C. Fiorino (IT)</i>
15:45 - 16:15	Coffee break							

BARCELONA • TUESDAY SEPTEMBER 14, 2010

	ROOM 1 (CL)	ROOM 2 (CL)	ROOM 3 (BT)	ROOM 4 (PH)	ROOM 5 (PH)	ROOM 6 (RB)	ROOM 7 (RTT)	ROOM 8
PROFFERED PAPERS 16:15 - 17:30	<p>Up-date of phase III randomized trials in HNC</p> <ul style="list-style-type: none"> • A randomized trial of hyperbaric O2 in prevention of late toxicity <p><i>P. Levendag (NL)</i> <i>Discussant: V. Grégoire (BE)</i></p> <ul style="list-style-type: none"> • TROG RT-QA tirapazamine trial <p><i>J. Giralt (SP)</i> <i>Discussant: J. Bernier (CH)</i></p> <ul style="list-style-type: none"> • Randomised trial of external beam radiotherapy alone or with high-dose-rate brachytherapy boost in localised prostate cancer <p><i>P. Hoskin (UK)</i> <i>Discussant: J. Lebesque (NL)</i></p> <ul style="list-style-type: none"> • Long term results of immediate post-operative radiotherapy after radical prostatectomy in PT3N0 prostate cancer (EORTC 22911) <p><i>M. Bolla (FR)</i> <i>Discussant: T. Wiegand (NL)</i></p> <ul style="list-style-type: none"> • Final results of randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer <p><i>L. Cionini (IT)</i> <i>Discussant: tbc</i></p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Proffered Papers</p>	<p>Symposium on EU Projects</p> <ul style="list-style-type: none"> • ALLEGRO • A. Ottolenghi (IT) • GENEPI2 • G. Heeren (BE) • MAESTRO • R. Hugon (FR) • ULICE • R. Orecchia (IT)
AWARD SESSION 17:30 - 18:00	<p>Introduction by György Kovács</p> <p>Iridium Award</p> <p>From "escargot" to 3D image guidance</p> <p><i>D. Ash (UK)</i></p>							
AWARD SESSION 18:00 - 18:30	<ul style="list-style-type: none"> • Varian award • Jack Fowler, University of Wisconsin Award • Accuray award 							
18:30 - 19:30	ESRO Programme School Symposium & Reception							

BARCELONA • WEDNESDAY SEPTEMBER 15, 2010

	ROOM 1 (CL)	ROOM 2 (CL)	ROOM 3 (MIXED)	ROOM 4 (PH)	ROOM 5 (PH)	ROOM 6 (RB)	ROOM 7 (RTT)	ROOM 8	
TEACHING LECTURE 08:00 - 08:40	<p>Recent developments in brain metastasis - review of randomized trials</p> <p><i>U. Riccardi (IT)</i></p>	<p>Biological rational of chemo-radiation</p> <p><i>V. Favaudon (FR)</i></p>	<p>Selection Criteria for brachytherapy in partial breast irradiation - Recommendations of the GEC-ESTRO breast cancer working group</p> <p><i>C. Polgar (HU)</i></p>	<p>Quality assurance of image guided radiotherapy devices</p> <p><i>M. Stock (AT)</i></p>	<p>Physics QA in brachytherapy</p> <p><i>FA. Siebert (DE)</i></p>	<p>Importance of normal tissue stem cells in radiotherapy</p> <p><i>R. Coppes (NL)</i></p>	<p>Modern approaches to palliative RT</p> <p><i>J. W. Leer (NL)</i></p>	<p>07:30 - 10:00 Head and neck contouring</p> <p><i>C. Grau (DK)</i> <i>J. Giralt (ES)</i></p>	
SYMPOSIUM 08:40 - 10:00	<p>New developments in neuro-oncology</p> <ul style="list-style-type: none"> • Disease progression or pseudo progression after concomitant radiochemotherapy treatment. Pitfalls in neurooncology <p><i>A. Brandes (IT)</i></p> <ul style="list-style-type: none"> • Temozolomide and radiotherapy in glioblastoma. Update of the EORTC trial and perspectives <p><i>R. Mirimanoff (CH)</i></p> <ul style="list-style-type: none"> • New strategies and treatment of grade III glioma <p><i>M. Weller (CH)</i></p>	<p>Organ dose tolerance: from bench to bedside</p> <p>JOINT SESSION WITH BIOLOGY</p> <ul style="list-style-type: none"> • Introduction and QUANTEC perspective <p><i>W. Dörr (DE)</i></p> <ul style="list-style-type: none"> • Spinal cord + brain (Biological) <p><i>A. van der Kogel (NL)</i></p> <ul style="list-style-type: none"> • Spinal cord + brain (Clinical) <p><i>C. Nieder (NO)</i></p> <ul style="list-style-type: none"> • Vascular / cardiovascular (Biological) <p><i>M.C. Vozenin-Brotans (FR)</i></p> <ul style="list-style-type: none"> • Vascular / cardiovascular (Clinical) <p><i>B. Aleman (NL)</i></p>	<p>Patterns of Care in Brachytherapy - where we are going to?</p> <ul style="list-style-type: none"> • Introduction and general information <p><i>F. Guedea (ES)</i></p> <ul style="list-style-type: none"> • Technical background and data security <p><i>G. Kovács (DE)</i></p> <ul style="list-style-type: none"> • Results by regions: Southern Europe <p><i>C. Marchetti (IT)</i></p> <ul style="list-style-type: none"> • Results of the patterns of care project in Brachytherapy 2007 for Western Europe <p><i>J. Venselaar (NL)</i></p> <ul style="list-style-type: none"> • Central Europe <p><i>H. Stankusova (CZ)</i></p> <ul style="list-style-type: none"> • Nordic Countries <p><i>T. Hellebust-Paulsen (NO)</i></p> <ul style="list-style-type: none"> • Latin America <p><i>A. Poitevin (MX)</i></p> <ul style="list-style-type: none"> • Conclusions and the PCB project in the future <p><i>F. Guedea (ES)</i></p>	<p>Cone Beam CT Guided RT</p> <ul style="list-style-type: none"> • Image formation and image quality <p><i>M. van Herk (NL)</i></p> <ul style="list-style-type: none"> • Image registration: target localization and deformation <p><i>M. Kessler (USA)</i></p> <ul style="list-style-type: none"> • Correction strategies for cone-beam CT guided radiotherapy <p><i>P. Reimerjier (NL)</i></p>	<p>New trends in Brachytherapy</p> <p>JOINT SESSION WITH BRACHYPHYSICS</p> <ul style="list-style-type: none"> • New sources in brachytherapy <p><i>D. Baltas (DE)</i></p> <ul style="list-style-type: none"> • Inhomogeneity corrections <p><i>A.C. Tedgren (SE)</i></p> <ul style="list-style-type: none"> • Pre-, online- and post plan - What levels of accuracy can we achieve? <p><i>M. de Brabandere (BE)</i></p>	<p>Importance of PI3K signalling for radiation therapy</p> <ul style="list-style-type: none"> • PI3K signalling in cancer and therapeutic implications <p><i>A. Carrero (ES)</i></p> <ul style="list-style-type: none"> • PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in vivo <p><i>EC Holland (USA)</i></p> <ul style="list-style-type: none"> • PI3K-AKT signalling as regulatory component of DNA-PK-dependent DNA double-strand break repair <p><i>HP. Rodemann (DE)</i></p>	<p>Importance of normal tissue stem cells in radiotherapy</p> <p><i>R. Coppes (NL)</i></p>	<p>Palliative RT</p> <ul style="list-style-type: none"> • Using cone beam CT for one stop simulation and treatment in palliative settings <p><i>M. Kamphuis (NL)</i></p> <ul style="list-style-type: none"> • Spinal cord compression - patient positioning and immobilisation procedures <p><i>Y. Van der Linden (NL)</i></p> <ul style="list-style-type: none"> • Optimisation of palliative RT based on patient reported outcome <p><i>D. Vordermark (DE)</i></p>	

BARCELONA • WEDNESDAY SEPTEMBER 15, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (MIXED)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)
10:00 - 10:30	Coffee break						
PROFFERED PAPERS 10:30 - 11:30	Proffered Papers	Proffered Papers	ESTRO - ASTRO JOINT SYMPOSIUM Thinking ahead: symposium on new biological tools and nanotechnology for radiotherapy	Advanced Correction Strategies • Adaptive radiotherapy <i>J.J. Sonke (NL)</i> • Online plan selection of pelvic tumours <i>G. Meijer (NL)</i> • Online planning and delivery technique for palliative radiotherapy of bone metastases <i>D. Letourneau (CA)</i>	Proffered Papers	Proffered Papers	Results of ESTRO's 'train the trainer' programme Serbia: <i>J. Stevanovic</i> Estonia: <i>N. Tover</i> A course that became an educational project in Croatia <i>V. Karadzica</i> Roundtable Discussion
AWARD LECTURE 11:30 - 12:00	Breur award Rectal cancer: does research translate into outcome? <i>K. Haustermans (BE)</i>						
PLENARY 12:00 - 12:45	Highlights of Phase III randomized trials • First results of the Accelerated, Carbogen breathing and nicotinamide (ARCON) randomized trial in head and neck cancer <i>H. Kaanders (NL)</i> DISCUSSANT: <i>J. Overgaard (DK)</i> • First results of a randomized trial comparing cisplatin 5FU-RT to mitomycin 5FU-RT in HNC <i>V. Budach (DE)</i> DISCUSSANT: <i>H. Langendijk (NL)</i> • Treatment of patients with Hodgkin lymphoma in early favourable stages: Final analysis of the randomized German Hodgkin Study Group (GHSG) trial HD10 <i>H. Eich (DE)</i> DISCUSSANT: <i>tbc</i>						
12:45 - 14:30	Lunch - Poster viewing - Satellite Symposia						

BARCELONA • WEDNESDAY SEPTEMBER 15, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (MIXED)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)	Room 8
SYMPOSIA 14:30 - 15:45	Radiation responses of normal and cancer stem cells JOINT SESSION BIOLOGY-CLINICAL • Radioresistance of skin stem cells through the FGF2 pathway <i>M. Martin (FR)</i> • Bone marrow stem cells <i>Speaker tbc</i> • Cancer stem cells from biology to clinical implications <i>M. Krause (DE)</i>	ESTRO / ESMO / ESSO JOINT SYMPOSIUM Liver metastases: Towards more curative approaches? • New insights systematic treatment <i>C.H. Koehne (DE)</i> • Stereotactic RT <i>D. Peiffert (FR)</i> • Intervention radiology <i>T. DeBaere (FR)</i> • Surgical treatment of liver metastases <i>J. Rothbarth (NL)</i>	ESTRO / EANM JOINT SYMPOSIUM Guidelines on implementing PET-CT in radiotherapy treatment planning • Introduction <i>V. Grégoire (BE)</i> • Interpretation and quantitative analysis of PET/CT studies <i>W.A. Weber (DE)</i> • Image reconstruction and segmentation <i>L. Lee (BE)</i> • Overview of the clinical use of PET-CT in radiotherapy planning <i>A. Chiti (IT)</i> • Conclusion - <i>A. Chiti (IT)</i>	Physics debate	Physics Debate The pursuit of conformal therapy: • Sense <i>D. Verellen (BE)</i> • Nonsense <i>DR. Olsen (NO)</i>	Radiation-induced immune responses and therapeutic outcome in radiation oncology JOINT SESSION WITH CLINICAL • Immunogenic tumour cell death triggered by irradiation: human perspectives <i>A. Tesnière (FR)</i> • Radiation-induced heat shock protein 70 and therapeutic implications <i>G. Multhoff (DE)</i> • Effect of immunomodulators on the radiation response of normal mucosa in vivo <i>J. Haagen (DE)</i>	Presentations on research activities in Europe: What is done by RTTs • Implications of RTT in EORTC research <i>F. Duclos (CH)</i> • Facilitating RTT participation in research <i>A. Clayton - Lea (UK)</i> • Guide to research <i>L. Marignol (IE)</i> • Optimising CT guided radiotherapy for breast cancer <i>HP. van der Laan (NL)</i>	ESTRO / PROS JOINT SYMPOSIUM Pediatric tumors in adults • Medulloblastoma in adults <i>L. Padovani (FR)</i> • Ewing sarcoma in adults <i>L. Claude (FR)</i> • Rhabdomyosarcoma in adults <i>J. Giralt (ES)</i>
15:45 - 16:15	Coffee break							
PROFFERED PAPERS 16:15 - 17:30	Proffered Papers	Debate: Is induction chemotherapy a standard of care in locally advanced head and neck cancer? • In favour of the motion <i>L. Liaira (IT)</i> • Is induction chemotherapy a standard of care in locally advanced head and neck cancer? No it is not <i>H. Langendijk (NL)</i>	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Proffered Papers	Panel discussion: the way forward for European research into normal tissue complications and second cancers following radiotherapy Organised by ALLEGRO Consortium • Introduction - <i>M. Baumann (DE)</i> • The risk of complication in radiotherapy - <i>H. Langendijk (NL)</i> • Q&A • The risk of second cancers in radiotherapy - <i>W. Dörr (DE)</i> • Q&A and wrap up
17:45	General Assembly							
20:00	Social evening							

BARCELONA • THURSDAY SEPTEMBER 16, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (MIXED)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)
TEACHING LECTURES 08:30 - 09:10	Integration of systemic therapies in HN radiotherapy <i>G. Calais (FR)</i>	Endometrial cancer. The changing role of radiation therapy <i>C. Creutzberg (NL)</i>	Up-date of the core curriculum for radiation oncologists <i>S. Magrini (IT)</i>	Non-rigid image registration - "How does it work?" <i>D. Hawkes (UK)</i>	Inverse planning and plan optimization - Opening the black box <i>T. Bortfeld (USA)</i>	Influence of chromatin remodelling and DNA repair in the radiation response <i>N. Foray (FR)</i>	Overview of fractionation modifications in head and neck cancer <i>P. Blanchard (FR)</i>
SYMPOSIUM 09:15 - 10:30	New challenges in head and neck cancers • Up date of the MRC IMRT randomized trial and dose escalation with IMRT <i>C. Nutting (UK)</i> • Enigmas and challenges in the diagnosis and treatment of HPV-related oropharyngeal cancer <i>B. O'Sullivan (CA)</i> • Update on EGFR targeting <i>K. Harrington (UK)</i>	Prostate image guided RT: clinical perspectives • Imaging for optimal target definition <i>V. Khoo (UK)</i> • Adaptive RT - organ motion, organ deformation <i>R. De Crevoisier (FR)</i> • Functional imaging assessment of prediction and response <i>R. Miralbell (CH)</i>	ESTRO / ESGO JOINT SYMPOSIUM Assessment and treatment of nodal disease in cervical cancer • PET CT imaging for the assessment of nodal spread in locally advanced cervical cancer <i>E. Leblanc (FR)</i> • Is there still a place (and a benefit in term of improving survival) for staging surgery in the era of PET CT imaging? <i>P. Morice (FR)</i> • Optimization of radiation therapy for patients with suspected or proven nodal metastases <i>I. Jürgenliemk-Schulz (NL)</i> • Should management of locally advanced adenocarcinoma and squamous cell carcinoma (with nodal spread) be similar? <i>G. Thomas (CA)</i>	Non-rigid image registration: applications • Lung <i>D. Sarrut (FR)</i> • Clinical use of non-rigid image registration in H&N cancer radiotherapy <i>P. Castadot (BE)</i> • Pelvis <i>K. Brock (CA)</i> • Non rigid registration of large deformations in the pelvic region and applications for adaptive radiation therapy <i>L. Bondar (NL)</i>	IMRT treatment verification - Lessons learned • IMRT credentialling using the radiological physics centre's anthropomorphic QA PHANTOMS <i>D. Followill (USA)</i> • Patient specific measurements for IMRT, is it really necessary? <i>J. Olafsson (SE)</i> • In vivo dosimetry as substitute of pre-treatment verification <i>B. Mijneer (NL)</i> • Going towards 3D-volume related gamma analysis <i>M. Dirck (NL)</i>	Re-irradiation JOINT SESSION BIOLOGY-CLINICAL • Normal tissue tolerance RO re-irradiation <i>W. Dörr (DE)</i> • Re-irradiation of brain tumors <i>S. Combs (DE)</i> • Re-irradiation in nasopharyngeal cancer <i>A. W. Lee (HK)</i>	Managing side effects: the RTT perspective • A review of the management of skin reactions / skin care <i>A. Clayton-Lea (IE)</i> • Oral care minimising the reaction; Eating; Speaking <i>M. Knöös (SE)</i> • Psychosocial issues «The role of the RT: recognition of psychosocial issues and when to refer patients for specialist care » <i>S. Dempsey (IE)</i>

BARCELONA • THURSDAY SEPTEMBER 16, 2010

	Room 1 (CL)	Room 2 (CL)	Room 3 (MIXED)	Room 4 (PH)	Room 5 (PH)	Room 6 (RB)	Room 7 (RTT)
10:30 - 11:00	Coffee break						
SYMPOSIUM 11:00 - 12:00	Image guided radiotherapy clinical perspectives between radiotherapy and clinical • Imaging and optimal target definition and dose painting in HNC <i>A. Grosu (DE)</i> • Imaging optimal target definition and dose painting in prostate cancer <i>M. Krengli (IT)</i>	Preferred papers	Preferred papers	My optimal (dream) proton / machine is... • Is passive scattering outdated? <i>H. Kooy (USA)</i> • Advantage and disadvantage of scanning techniques <i>T. Lomax (CH)</i> • Adding ions to the proton machine <i>M. Münter (DE)</i>	How to optimize MRI for treatment planning? • Functional MR for treatment planning <i>M. Leach (UK)</i> • Novel MR imaging sequences <i>E. Malinen (NO)</i> • Radiotherapy driven by MR imaging <i>M. Karlsson (SE)</i>	Potential advantages and pitfalls of anti-vascular and anti-angiogenics treatments • Visualisation of tumor vasculature alter anti-angiogenic therapy <i>D. Duda (USA)</i> • Tumour adaptive responses to antiangiogenic therapies <i>O. Casanovas (ES)</i> • Targeting endothelial growth factor <i>F. Paris (FR)</i>	Managerial issues • Opening a new department <i>J. Davis (UK)</i> • Introducing new technology - a team approach <i>P. Scalliet (BE)</i> • Technological evolution in radiation therapy on a department level <i>Speaker: tbc</i>
12:00 - 12:45	Debate: Dose painting - Do we need: • a small brush <i>S. Bentzen (USA)</i> or • a large brush <i>V. Khoo (UK)</i>						



ONLINE REGISTRATION

Registering through the ESTRO website is simple and will only take a few minutes. The ESTRO website can be consulted at www.estro.org (click “events”, “ESTRO 29” and then “register online”). Please follow the instructions included on the electronic registration form before submitting your registration and do not send it again by fax or post. Receipt of registration will be acknowledged electronically.

PAYMENT INFORMATION

Payments can be made either by credit card through our secured website or by bank transfer.

For all questions concerning registration and payments, please contact: Jill Barnard (jill.barnard@estro.org).

REGISTRATION FEE (PRICES IN EURO)

Reduced fees apply when the payment is received before specific deadlines:

Late registration rate deadline: August 6, 2010

Desk registration rate: as of August 7, 2010

The registration fee to the conference includes access to the scientific sessions and exhibition area, the programme and abstract books, coffee and lunches, the invitation to the opening reception and the social evening.

CONFIRMATION OF REGISTRATION

Upon receipt of your registration form, a confirmation of your registration will be forwarded to you electronically.

CANCELLATION OF REGISTRATION

In case of cancellation, a full refund of the registration fee, minus handling charges of 15%, may be obtained up to 3 months before the meeting. Between 3 months and 1 month before the meeting, the refund will amount to 50% of the fee. No refund will be possible if the cancellation is postmarked after August 12, 2010.

CONFERENCE	LATE	DESK
DEADLINES	AS OF 26/02/2010	AS OF 07/08/2010
1 day registration RTT member	190	190
1 day registration ESTRO member (exc. RTT)	290	290
1 day registration non member	405	405
Student *	235	295
RTT member	330	430
Junior Member	390	530
Member	530	670
Non member	755	935
Accompanying person **	135	135
PRE-CONFERENCE COURSES		
RTT member/Junior member/Student	150	220
Member	185	240
Non member	230	280
NATIONAL ASSOCIATIONS DAY		
	50	100

* To register as a student you should send your updated student card after doing the registration and before paying, institute letters are not accepted.

** The registration fee for accompanying persons includes access to the opening reception, the social evening and the exhibition area.



CONFERENCE SECRETARIAT

ESTRO office
Av. Mounierlaan 83
1200 Brussels (Belgium)
Tel: +32 2 775 93 40
Fax: +32 2 779 54 94
www.estro.org

ESTRO 